Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emily Bergsland

Showing results (11-20 of 64) with videos related to

Pageof 7
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 4, 2005
Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancerFairooz F Kabbinavar, Julie Hambleton, Robert D Mass, et al.
Endocrine Pathology|November 18, 2024
Progression of Low-Grade Neuroendocrine Tumors (NET) to High-Grade Neoplasms Harboring the NEC-Like Co-alteration of RB1 and TP53Nancy M Joseph, Sarah E Umetsu, Grace E Kim, et al.
JCO Precision Oncology|June 23, 2022
Checkpoint Inhibitor Immunotherapy to Treat Temozolomide-Associated Hypermutation in Advanced Atypical Carcinoid Tumor of the LungFangdi Sun, James P Grenert, Lisa Tan, et al.
Psycho-Oncology|August 19, 2003
Couples therapy at end of lifeDavid C Mohr, Patricia J Moran, Carolynn Kohn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 31, 2002
Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancerFairooz Kabbinavar, Herbert I Hurwitz, Louis Fehrenbacher, et al.
JCO Precision Oncology|February 1, 2022
Complete Response and Immune-Mediated Adverse Effects With Checkpoint Blockade: Treatment of Mismatch Repair-Deficient Colorectal Neuroendocrine CarcinomaJulia Whitman, Adel Kardosh, Luis Diaz, et al.
Abdominal Imaging|March 31, 2015
Simultaneous (68)Ga-DOTA-TOC PET/MRI with gadoxetate disodium in patients with neuroendocrine tumorThomas A Hope, Miguel Hernandez Pampaloni, Eric Nakakura, et al.
JCO Oncology Practice|May 1, 2020
Modifying Practices in GI Oncology in the Face of COVID-19: Recommendations From Expert Oncologists on Minimizing Patient RiskEmil Lou, Shaalan Beg, Emily Bergsland, et al.
Cancers|June 2, 2021
The Immunotherapy Landscape in Adrenocortical CancerGuillaume J Pegna, Nitin Roper, Rosandra N Kaplan, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|February 12, 2025
Burdens of Gastroenteropancreatic Neuroendocrine Neoplasm by Diverse Race and Ethnicities- A Rigorous Structural Equation ModelingAlan Paciorek, Claire Mulvey, Meg McKinley, et al.
Pageof 7

Showing results (11-20 of 64) with videos related to

Sort By:
Pageof 7
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 4, 2005
Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancerFairooz F Kabbinavar, Julie Hambleton, Robert D Mass, et al.
Endocrine Pathology|November 18, 2024
Progression of Low-Grade Neuroendocrine Tumors (NET) to High-Grade Neoplasms Harboring the NEC-Like Co-alteration of RB1 and TP53Nancy M Joseph, Sarah E Umetsu, Grace E Kim, et al.
JCO Precision Oncology|June 23, 2022
Checkpoint Inhibitor Immunotherapy to Treat Temozolomide-Associated Hypermutation in Advanced Atypical Carcinoid Tumor of the LungFangdi Sun, James P Grenert, Lisa Tan, et al.
Psycho-Oncology|August 19, 2003
Couples therapy at end of lifeDavid C Mohr, Patricia J Moran, Carolynn Kohn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 31, 2002
Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancerFairooz Kabbinavar, Herbert I Hurwitz, Louis Fehrenbacher, et al.
JCO Precision Oncology|February 1, 2022
Complete Response and Immune-Mediated Adverse Effects With Checkpoint Blockade: Treatment of Mismatch Repair-Deficient Colorectal Neuroendocrine CarcinomaJulia Whitman, Adel Kardosh, Luis Diaz, et al.
Abdominal Imaging|March 31, 2015
Simultaneous (68)Ga-DOTA-TOC PET/MRI with gadoxetate disodium in patients with neuroendocrine tumorThomas A Hope, Miguel Hernandez Pampaloni, Eric Nakakura, et al.
JCO Oncology Practice|May 1, 2020
Modifying Practices in GI Oncology in the Face of COVID-19: Recommendations From Expert Oncologists on Minimizing Patient RiskEmil Lou, Shaalan Beg, Emily Bergsland, et al.
Cancers|June 2, 2021
The Immunotherapy Landscape in Adrenocortical CancerGuillaume J Pegna, Nitin Roper, Rosandra N Kaplan, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|February 12, 2025
Burdens of Gastroenteropancreatic Neuroendocrine Neoplasm by Diverse Race and Ethnicities- A Rigorous Structural Equation ModelingAlan Paciorek, Claire Mulvey, Meg McKinley, et al.
Pageof 7